Canmab 440 mg Injection

Canmab 440 mg Injection is engineered to tackle aggressive cancers that overexpress the HER2 protein. By blocking the receptors that fuel cell division, Trastuzumab effectively "starves" the tumor. In many cases, it is used in combination with chemotherapy (such as paclitaxel or docetaxel) to provide a comprehensive attack on malignant cells.

Key Clinical Advantages of Biocon Canmab

• Targeted Mechanism: Specifically attacks cancer cells while minimizing damage to healthy, non-HER2-expressing cells.

• Proven Biosimilarity: Clinically tested to show no meaningful differences in safety, purity, or potency compared to Herceptin.

• Improved Survival: Significantly increases progression-free survival (PFS) and overall survival (OS) in both breast and gastric cancer patients.

• Multi-Dose Vial: The 440 mg strength is designed for efficient clinical use and precise weight-based dosing.

Administration & Cold-Chain Protocols

1. Administration: Must be administered as an Intravenous (IV) Infusion by a qualified oncology professional. It is never given as an IV bolus or push.

2. Dosing Schedule: Typically follows a loading dose (e.g., 8 mg/kg) followed by maintenance doses (e.g., 6 mg/kg) every 3 weeks, or weekly schedules depending on the regimen.

3. Strict Storage: Must be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze or shake the vial.

4. Monitoring: Patients require regular cardiac monitoring (LVEF assessments), as Trastuzumab can affect heart function, especially when used with anthracyclines.